Drugs / YTS104
YTS104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05913804 | Jun 2023 → Dec 2025 overdue | refractory plasma cell neoplasm | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YTS104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05913804 ↗ |
| Known as | YTS104 Cell injection | “YTS104 Cell injection(LILRB4 dual STAR-T Cell Injection/BCMA LILRB4 Dual STAR-T Cell Injection)) is a new STAR-T cell transfected by lentivirus.” NCT05913804 ↗ |
| Known as | YTS104 Cells injection | “Biological: YTS104 Cells injection” NCT05913804 ↗ |
| Modality | Cell therapy | “is a new STAR-T cell transfected by lentivirus.” NCT05913804 ↗ |
| Route | Intravenous | “YTS104 cells injection will be intravenously infused” NCT05913804 ↗ |